ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO744

Impact of Blood Pressure on Mortality in Patients Undergoing Peritoneal Dialysis

Session Information

Category: Hypertension and CVD

  • 1502 Hypertension and CVD: Clinical‚ Outcomes‚ and Trials

Authors

  • Kim, Jwa-kyung, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Korea (the Republic of)
  • Lee, Dong Hee, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Korea (the Republic of)
  • Kim, Sungmin, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Korea (the Republic of)
  • Kim, Sung Gyun, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Korea (the Republic of)
Background

A recent KDIGO guideline recommends intensive blood pressure (BP) control in chronic kidney disease. However, no consensus on the optimal BP has been made in the dialysis population. With a well-characterized peritoneal dialysis (PD) cohort, we evaluated the impact of BP on long-term mortality.

Methods

With the incident PD patients who had more than 6 months' follow-up between 2000 to 2019 (n=490), the relationship between BP and mortality rate adjusting for age, sex, BMI, and comorbidities was analyzed. Mean BP levels at 3-6 months after PD initiation were studied for predicting all-cause mortality as well as fatal and non-fatal cardiovascular (CV) events.

Results

During the median PD duration of 40 months (IQR, 22 to 66), the mortality rate was 50.3 per 1000 patient-year (102 cases). Overall, the survival rates were much better than previously known; the 3-. 5- and 10-year patient survival rate was 87.6%, 79.1%, and 55.4%. It markedly differed according to the presence of diabetes; the 3, 5, and 10-year mortality were 84%, 71.4%, and 40.7% in diabetes and 92%, 89.0 %, and 74% in non-diabetes, respectively (p<0.001). In multivariate Cox proportional hazard modeling, the risk of death had a U-curved association with systolic BP (SBP) with a nadir between 120 and 140 mmHg. Based on this, the hazard ratios (HR, 95% confidence interval [CI]) for all-cause mortality with SBP <120 mmHg, 140-160 mmHg, and ≥160 mmHg were 3.3 (1.7-6.4), 1.68 (0.83-3.4), and 2.3 (1.1-4.9) after adjusting age, sex, diabetes, body mass index, and previous coronary artery diseases. Similarly, fatal and non-fatal CV risks were significantly increased when SBP <120 mmHg or ≥160 mmHg.

Conclusion

Patients who started PD in the 2000s showed improved survival rates than before. Low SBP < 120 mmHg showed the highest mortality risk. And high SBP > 160 mmHg was also associated with increased mortality even after adjusting for well-known risk factors.